Skip to main content

Table 4 Laboratory values at baseline and in the acute and chronic periods following TACE

From: Liver function changes after transarterial chemoembolization in US hepatocellular carcinoma patients: the LiverT study

Laboratory parameter Patient number, n Baseline
(value closest to index TACE)
Acute period (highest value) P-value acute vs baseline Chronic period (latest value) P-value chronic vs baseline
Bilirubin, mg/dL 462      
 Mean (SD)   1.5 (1.1) 2.2 (2.9) 2.3 (4.1)
 Median (range)   1.2 (0.09–6.9) 1.4 (0.3–37.9) P < .0001 1.2 (0.2–41.3) P = .008
Albumin, g/dL 442      
 Mean (SD)   3.2 (0.7) 2.9 (0.7) 3.1 (0.7)
 Median (range)   3.3 (1.6–4.9) 2.8 (1.0–4.8) P < .0001 3.1 (1.4–4.8) P < .0001
AST, U/L 446      
 Mean (SD)   75.9 (61.5) 152.6 (270.4)   88.5 (187.3)  
 Median (range)   62 (11–844) 82 (13–3341) P < .0001 60 (9–3739) P = .600
ALT, U/L 441      
 Mean (SD)   59.5 (49.6) 122.1 (266.8)   62.1 (82.8)  
 Median (range)   45 (9–450) 60 (7–3198) P < .0001 42 (7–1122) P = .08
INR 251      
 Mean (SD)   1.3 (0.4) 1.6 (0.9)   1.5 (0.6)  
 Median (range)   1.2 (0.9–3.2) 1.3 (0.9–6.9) P < .0001 1.2 (0.9–6.9) P < .0001
  1. Acute period, 0–29 days after TACE; chronic period, 30–90 days after TACE
  2. ALT alanine transaminase, AST aspartate transaminase, INR international normalized ratio, SD standard deviation, TACE transarterial chemoembolization